VYNE Therapeutics Q3 Adj EPS $(1.59) Beats $(1.97) Estimate, Sales $114.00K Down From $167.00K YoY
Portfolio Pulse from Benzinga Newsdesk
VYNE Therapeutics reported Q3 adjusted EPS of $(1.59), surpassing the $(1.97) estimate, marking a 19.29% beat and a 36.9% improvement from last year's $(2.52) per share. However, sales declined to $114K from $167K YoY, a 31.74% decrease.
November 13, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
VYNE Therapeutics exceeded EPS estimates for Q3 but reported a significant decline in sales compared to the same quarter last year.
While VYNE's EPS beat may be viewed positively, the substantial decrease in sales could raise concerns about the company's revenue growth and future profitability. The mixed results present a neutral short-term impact as the market digests both the positive EPS beat and the negative sales performance.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100